联系方式

手机号码：13026930224

电子邮箱：zhangzl@mailbox.gxnu.edu.cn

办公地址：重点实验室2号楼2403

研究方向

生物无机化学

学历背景

2017-2020 广西师范大学化学与药学学院(博士)

2014-2017 广西师范大学化学与药学学院(硕士）  

工作经历

2021.1-至今，省部共建药用资源化学与药物分子工程国家重点实验室，专职科研岗，讲师

代表性论文

1. Zhang ZL, Yang TF, Zhang JZ, Li WJ, Li SH, Sun HB, Liang H*, Yang F*. Developing a novel indium(III) agent based on human serum albumin nanoparticles: integrating bioimaging and therapy. Journal of Medicinal Chemistry, 2022, 65: 5392−5406. (药物化学顶级期刊，IF=8.039)

2. Zhang ZL, Yu P, Gou Y, Zhang JZ, Li SH, Cai ML, Sun HB, Yang F*, Liang H*. Novel brain-tumor-inhibiting copper(II) compound based on a human serum albumin (HSA)-cell penetrating peptide conjugate. Journal of Medicinal Chemistry, 2019, 62: 10630−10644.

3. Zhang JZ, Zhang ZL, Jiang M, Li SH, Yuan HL, Sun HB, Yang F*, Liang H*. Developing a novel gold(III) agent to treat glioma based onthe unique properties of apoferritin nanoparticles: inducing lethal autophagy and apoptosis. Journal of Medicinal Chemistry, 2020, 63: 13695−13708.（共同第一作者）

4. Zhang ZL,Gou Y, Wang J, Qi JX, Zhang Y, Liang SC*, Liang H*, Yang F*. Four copper (II) compounds synthesized by anion regulation: structure, anticancer function andanticancer mechanism. European Journal of Medicinal Chemistry, 2016, 121: 399−409.(药物化学顶级期刊，IF=7.088)

5. Gou Y, Zhang ZL, Li DY, Zhao L, Cai ML, Sun ZW, Li Y, Zhang Y, Khan H, Sun H, Wang T, Liang H*, Yang F*. HSA-based multi-target combination therapy: regulating drugs' release from HSA and overcoming single drug resistance in a breast cancer model. Drug Delivery, 2018, 25: 321−329.(IF=6.819，共同第一作者)

6. Zhang ZL, Zhang JZ, Jiang M,Zhao L, Li SH, Sun HB, Yang F*, Liang H*. Human serum albumin-based dual-agent delivery systems for combination therapy: acting against cancer cells and inhibiting neovascularization in the tumor microenvironment. Molecular Pharmaceutics, 2020, 17: 1405−1414.(IF=5.364，Top 期刊，被选为期刊封面论文)

7. Wang J, Gou Y, Zhang ZL, Yu P, Qi JX, Qin QP, Sun HB, Wu XY, Liang H, Yang F*. Developing an anticancer copper(II) multitarget pro-drug based on the His146 residue in the IB subdomain of modified human serum albumin. Molecular Pharmaceutics, 2018, 15: 2180−2193.(共同第一作者).

8. Zhang Y, Zhang ZL, Gou Y, Jiang M, Khan H, Zhou ZP*, Liang H*, Yang F*. Design an anticancer copper(II) pro-drug based on the flexible IIA subdomain of human serum albumin. Journal of Inorganic Biochemistry, 2017, 172: 1–8. (IF=4.336，共同第一作者).

科研项目

(1) 广西科学自然基金-青年项目：基于脱铁铁蛋白特性发展诊疗一体化抗肿瘤先导金属化合物，8万元。（2022.04-2025.03）

(2) 省部共建药用资源化学与药物分子工程国家重点实验室人才引进课题：基于内源性蛋白特性发展诊疗一体化金属药物，50万元。（2021.05-2023.05）

(3) 广西师范大学人才引进项目，10万元。